See the latest news and media coverage for Corline. We track all announcements, press releases, and industry mentions in real time, all in one place.
Antithrombotic and antiinflammatory surface coating solutions provider
corline.seLast updated
In short: Corline achieved revenue growth and secured a 10-year license agreement after regulatory approvals for the Globe system.
After the approval from the US FDA in September 2025, Health Canada approved the Globe Pulsed Field System, which uses Corlines CHS coating for the treatment of atrial fibrillation.
The study shows good kidney function after 60 months and indicates better results compared to untreated paired kidneys.
Net sales increased to 4,291 KSEK. The result after financial net was -2,501 KSEK. Issue and loan from Kardium provided 18.5 MSEK.
The annual report for the accounting year 2025 is made available on the company's website www.corline.se.
On 26.08.2026, Corline Biomedical AB presented the latest quarterly report for the quarter ending on 30.06.2026.For the latest quarterly period...
Corline Biomedical AB is listed on First North Growth Market (CLBIO) and sells its self-developed product CHS™ to medical technology customers who need a high-quality antithrombotic...
Corline Biomedical AB will release its next earnings report on Aug 21, 2026.
The Corline Biomedical AB EPS (TTM) is -0.57.
Track Corline and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Corline and other trending companies.